If present, the potential causal link between activin A and diabetes would hold great promise for the development of new effective therapies, in which targeting activin A and its receptors could potentially restore normal β-cell function, improve insulin sensitivity, and reduce inflammation in diabetic patients. The gene discussed is INS; the disease is diabetes mellitus.